Intranasal Vaccination with rePcrV Protects against Pseudomonas aeruginosa and Generates Lung Tissue-Resident Memory T Cells

Figure 6

rePcrV vaccine efficacy remains independent of IL-7. (a) Experimental timeline. Lung CFU 24 hours after infection in naïve mice, rePcrV-immunized mice, and FTY720 treatment-immunized mice with or without anti-IL-7 Ab (). (b) Representative H and E stains in naïve mice, rePcrV-immunized mice, and FTY720 treatment-immunized mice with or without anti-IL-7 Ab (). Significant differences were calculated using unpaired -test. The “n.s.” means “no significant difference.”

(a)

(b)